#2-84E. Durable Remission in ITP: Short-Course Ianalumab and Eltrombopag (NEJM, 2025)

How can clinicians help patients with Immune Thrombocytopenia (ITP) move beyond indefinite, long-term second-line treatments to achieve sustained remission off-therapy? The Phase 3 VAYHIT2 trial addresses this critical unmet need by investigating a short-course, 4-month regimen of ianalumab, a B-cell targeting antibody that blocks BAFF receptors, combined with the TPO-RA eltrombopag in adult ITP patients who relapsed or showed an insufficient response after glucocorticoids. The primary result demonstrated that the ianalumab combination significantly prolonged the time to treatment failure compared to placebo (e.g., HR 0.55; P=0.04), indicating a greater probability of maintaining a safe platelet count after eltrombopag was successfully tapered and discontinued. This finding suggests a potentially disease-modifying strategy that could transform treatment goals from continuous management to durable remission. However, it is essential to consider the limitation that the cohort included only patients relatively early in the course of ITP who had failed first-line glucocorticoids, potentially limiting the generalizability to more advanced or refractory cases. Ultimately, this study offers vital insights for physicians, suggesting a pathway to reduce the burden of chronic medication and optimize long-term outcomes for ITP patients.

Citation: Cuker A, Stauch T, Cooper N, et al. Ianalumab plus Eltrombopag in Immune Thrombocytopenia. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2515168

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.